JP2010504973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504973A5 JP2010504973A5 JP2009530406A JP2009530406A JP2010504973A5 JP 2010504973 A5 JP2010504973 A5 JP 2010504973A5 JP 2009530406 A JP2009530406 A JP 2009530406A JP 2009530406 A JP2009530406 A JP 2009530406A JP 2010504973 A5 JP2010504973 A5 JP 2010504973A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- disorder
- pharmaceutical composition
- disease
- cns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84747106P | 2006-09-26 | 2006-09-26 | |
| US60/847,471 | 2006-09-26 | ||
| PCT/US2007/020765 WO2008039489A2 (en) | 2006-09-26 | 2007-09-25 | 5-substituted quinazolinone derivatives as antitumor agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013210802A Division JP5901599B2 (ja) | 2006-09-26 | 2013-10-08 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010504973A JP2010504973A (ja) | 2010-02-18 |
| JP2010504973A5 true JP2010504973A5 (https=) | 2010-11-18 |
| JP5388854B2 JP5388854B2 (ja) | 2014-01-15 |
Family
ID=39230813
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530406A Expired - Fee Related JP5388854B2 (ja) | 2006-09-26 | 2007-09-25 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
| JP2013210802A Expired - Fee Related JP5901599B2 (ja) | 2006-09-26 | 2013-10-08 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
| JP2015218025A Expired - Fee Related JP6133383B2 (ja) | 2006-09-26 | 2015-11-06 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
| JP2017082496A Ceased JP2017165744A (ja) | 2006-09-26 | 2017-04-19 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013210802A Expired - Fee Related JP5901599B2 (ja) | 2006-09-26 | 2013-10-08 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
| JP2015218025A Expired - Fee Related JP6133383B2 (ja) | 2006-09-26 | 2015-11-06 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
| JP2017082496A Ceased JP2017165744A (ja) | 2006-09-26 | 2017-04-19 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US7635700B2 (https=) |
| EP (5) | EP2428513B1 (https=) |
| JP (4) | JP5388854B2 (https=) |
| KR (1) | KR101414786B1 (https=) |
| CN (6) | CN104910133A (https=) |
| AR (2) | AR063015A1 (https=) |
| AT (1) | ATE555104T1 (https=) |
| CA (1) | CA2663731C (https=) |
| CL (1) | CL2007002752A1 (https=) |
| CO (1) | CO6160323A2 (https=) |
| CR (1) | CR10712A (https=) |
| CY (3) | CY1112860T1 (https=) |
| DK (4) | DK2420497T3 (https=) |
| ES (4) | ES2634915T3 (https=) |
| HR (4) | HRP20120447T1 (https=) |
| HU (3) | HUE026827T2 (https=) |
| IL (3) | IL197716A (https=) |
| LT (2) | LT2420498T (https=) |
| ME (4) | ME02420B (https=) |
| MX (1) | MX2009003038A (https=) |
| MY (1) | MY150699A (https=) |
| NI (1) | NI200900040A (https=) |
| NZ (1) | NZ575830A (https=) |
| PE (1) | PE20080970A1 (https=) |
| PL (4) | PL2066656T3 (https=) |
| PT (3) | PT2420498T (https=) |
| RS (3) | RS54607B1 (https=) |
| RU (3) | RU2463298C2 (https=) |
| SI (4) | SI2428513T1 (https=) |
| TW (2) | TWI522351B (https=) |
| UA (1) | UA94964C2 (https=) |
| WO (1) | WO2008039489A2 (https=) |
| ZA (1) | ZA200901950B (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| ME02420B (me) * | 2006-09-26 | 2016-09-20 | Celgene Corp | 5-supstituirani derivati kinazolinona kao sredstva protiv raka |
| CA2704710C (en) | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| US8354417B2 (en) * | 2007-09-26 | 2013-01-15 | Celgene Corporation | Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
| US7786171B2 (en) | 2008-04-04 | 2010-08-31 | Abbott Laboratories | Amide derivatives as positive allosteric modulators and methods of use thereof |
| US8835506B2 (en) | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
| US20100160368A1 (en) * | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
| SI2378876T1 (sl) | 2008-12-19 | 2019-05-31 | Medicis Pharmaceutical Corporation | Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze |
| TWI546537B (zh) * | 2009-05-19 | 2016-08-21 | 維維亞生技公司 | 提供針對血液腫瘤之體外個人化藥物測試之方法 |
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| GEP20156418B (en) | 2009-07-13 | 2016-01-11 | Medicis Pharmaceutical Corp | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| CN101913846B (zh) * | 2010-08-11 | 2012-05-23 | 昆明理工大学 | 一种用煤泥磷石膏冶金废渣合成陶粒的方法 |
| DK2683708T3 (da) | 2011-03-11 | 2018-01-29 | Celgene Corp | Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf |
| PH12013501837A1 (en) * | 2011-03-11 | 2013-11-18 | Celgene Corp | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases |
| EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| AU2012249491B2 (en) | 2011-04-29 | 2016-12-15 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| EP2892887B1 (en) | 2012-09-04 | 2020-07-15 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| EP2892537A1 (en) * | 2012-09-10 | 2015-07-15 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| JP6359563B2 (ja) * | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| WO2014172436A1 (en) * | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| SMT201700513T1 (it) | 2013-05-01 | 2018-01-11 | Celgene Corp | Sintesi di 3-(5-ammino-2-metil-4-ossochinazolin-3(4h)-il) piperidin-2,6-dione |
| EP2991651A1 (en) | 2013-05-03 | 2016-03-09 | Celgene Corporation | Methods for treating cancer using combination therapy |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| CN103645259B (zh) * | 2013-12-12 | 2015-03-11 | 深圳海王药业有限公司 | 一种同时测定泊马度胺及其有关物质的方法 |
| TW201540323A (zh) | 2014-01-15 | 2015-11-01 | Celgene Corp | ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物 |
| US10294243B2 (en) | 2014-06-05 | 2019-05-21 | Bayer Cropscience Aktiengesellschaft | Bicyclic compounds as pesticides |
| EP3827836A1 (en) | 2014-06-27 | 2021-06-02 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| AU2015305449B2 (en) | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| TW201642857A (zh) | 2015-04-06 | 2016-12-16 | 西建公司 | 以組合療法治療肝細胞癌 |
| US10973822B2 (en) | 2015-07-02 | 2021-04-13 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| CA2996641A1 (en) | 2015-08-27 | 2017-03-02 | Celgene Corporation | Pharmaceutical compositions comprising 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| ES2963446T3 (es) * | 2015-09-29 | 2024-03-27 | Kangpu Biopharmaceuticals Ltd | Composición farmacéutica y aplicación de la misma |
| CA3006758A1 (en) | 2015-12-02 | 2017-06-08 | Celgene Corporation | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| KR102331013B1 (ko) * | 2016-01-14 | 2021-11-26 | 강푸 바이오파마슈티칼즈 리미티드 | 퀴나졸리논 유도체, 이의 제조방법, 약학 조성물 및 적용 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| KR102368555B1 (ko) | 2016-12-16 | 2022-02-28 | 강푸 바이오파마슈티칼즈 리미티드 | 조성물, 이의 적용 및 치료 방법 |
| CA3053805C (en) | 2017-02-13 | 2020-06-30 | Kangpu Biopharmaceuticals, Ltd. | Combination treating prostate cancer, pharmaceutical composition and treatment method |
| WO2018165142A1 (en) | 2017-03-07 | 2018-09-13 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| KR102014478B1 (ko) * | 2017-05-12 | 2019-08-26 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| US10717703B2 (en) | 2017-08-21 | 2020-07-21 | Celgene Corporation | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| SG11202006246PA (en) | 2018-01-17 | 2020-07-29 | Aurigene Discovery Tech Ltd | Substituted alkynylene compounds as anticancer agents |
| BR112020017053A2 (pt) | 2018-02-21 | 2020-12-15 | Celgene Corporation | Anticorpos que se ligam ao bcma e usos dos mesmos |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| CA3117978A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| WO2021105335A1 (en) | 2019-11-27 | 2021-06-03 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
| JP7852923B2 (ja) | 2019-11-27 | 2026-04-28 | キャプター セラピューティクス エス．エー． | セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法 |
| WO2021168314A1 (en) * | 2020-02-21 | 2021-08-26 | Plexium, Inc. | Quinazolinone compounds and related compounds |
| US20230255975A1 (en) | 2020-06-25 | 2023-08-17 | Celgene Corporation | Methods for treating cancer with combination therapies |
| KR20230066554A (ko) * | 2020-07-24 | 2023-05-16 | 이니팜, 인크. | 퀴나졸리논 hsd17b13 억제제 및 이의 용도 |
| US20240294489A1 (en) | 2020-08-03 | 2024-09-05 | Captor Therapeutics S.A. | Low molecular weight protein degraders and their applications |
| EP4198030A4 (en) * | 2020-08-14 | 2024-01-10 | Shanghaitech University | IMMUNO-REGULATORY COMPOUND AND ITS ANTITUMOR APPLICATION |
| AU2021377248B2 (en) | 2020-11-13 | 2025-12-18 | Inipharm, Inc. | Dichlorophenol hsd17b13 inhibitors and uses thereof |
| WO2022146151A1 (en) | 2020-12-30 | 2022-07-07 | Captor Therapeutics S.A. | Novel compounds which bind to cereblon, and methods of use thereof |
| WO2022255890A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| WO2022255889A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| CN116589445B (zh) * | 2022-02-14 | 2026-02-27 | 标新生物医药科技(上海)有限公司 | 基于喹唑啉取代戊二酰亚胺骨架的化合物及其应用 |
| CA3249074A1 (en) | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS |
| WO2024167423A1 (en) | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| CN116789530B (zh) * | 2023-05-16 | 2025-12-19 | 杭州师范大学 | 一种紫苏醇酚类衍生物及其制备方法和应用 |
| US12565492B2 (en) | 2024-08-09 | 2026-03-03 | Triana Biomedicines, Inc. | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1997563A (en) * | 1929-05-31 | 1935-04-09 | Karmazin Engineering Company | Method of making heat radiators |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| DE122007000079I2 (de) | 1996-07-24 | 2010-08-12 | Celgene Corp | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| NZ526622A (en) * | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| AU2002343220A1 (en) | 2001-11-09 | 2003-05-19 | Matsushita Electric Industrial Co., Ltd. | Moving picture coding method and apparatus |
| FR2837201A1 (fr) * | 2002-03-18 | 2003-09-19 | Servier Lab | Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US20050024328A1 (en) | 2003-07-23 | 2005-02-03 | Graham Oldfield | Control area selection in a computing device with a graphical user interface |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| KR20060124607A (ko) | 2003-11-06 | 2006-12-05 | 셀진 코포레이션 | 암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물 |
| CA2545725A1 (en) | 2003-11-14 | 2005-06-02 | Merck Sharp & Dohme Limited | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| KR20060109979A (ko) | 2003-12-02 | 2006-10-23 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| CA2560221C (en) | 2004-03-22 | 2010-12-07 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| US20050239842A1 (en) | 2004-04-23 | 2005-10-27 | Zeldis Jerome B | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
| CN101098694A (zh) | 2004-11-12 | 2008-01-02 | 细胞基因公司 | 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物 |
| ZA200704890B (en) | 2004-11-23 | 2008-09-25 | Celgene Corp | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| GB0506147D0 (en) | 2005-03-24 | 2005-05-04 | Merck Sharp & Dohme | Therapeutic agents |
| US20090298856A1 (en) | 2005-05-11 | 2009-12-03 | Rebecca Elizabeth Brown | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) |
| GB0509573D0 (en) | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
| JP2009532450A (ja) | 2006-04-05 | 2009-09-10 | アストラゼネカ アクチボラグ | 化合物 |
| CN101415689A (zh) | 2006-04-05 | 2009-04-22 | 阿斯利康(瑞典)有限公司 | 具有抗癌活性的经取代的喹唑啉 |
| CN101421253A (zh) | 2006-04-18 | 2009-04-29 | 阿斯利康(瑞典)有限公司 | 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物 |
| ME02420B (me) * | 2006-09-26 | 2016-09-20 | Celgene Corp | 5-supstituirani derivati kinazolinona kao sredstva protiv raka |
| CA2704710C (en) | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| US9095596B2 (en) | 2009-10-15 | 2015-08-04 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| WO2012068512A1 (en) | 2010-11-18 | 2012-05-24 | Deuteria Pharmaceuticals Llc | 3-deutero-pomalidomide |
| DK2683708T3 (da) | 2011-03-11 | 2018-01-29 | Celgene Corp | Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf |
| PH12013501837A1 (en) | 2011-03-11 | 2013-11-18 | Celgene Corp | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases |
| AU2012249491B2 (en) | 2011-04-29 | 2016-12-15 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| AU2013202104B2 (en) | 2012-01-13 | 2015-11-26 | Celgene Corporation | Biomarkers for the treatment of hepatocellular carcinoma |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| EP2892887B1 (en) | 2012-09-04 | 2020-07-15 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| EP2892537A1 (en) | 2012-09-10 | 2015-07-15 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| JP6359563B2 (ja) | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| WO2014151180A1 (en) | 2013-03-14 | 2014-09-25 | Celgene Corporation | Treatment of psoriatic arthritis using apremilast |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| CA2909579A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| NZ629456A (en) | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| SMT201700513T1 (it) | 2013-05-01 | 2018-01-11 | Celgene Corp | Sintesi di 3-(5-ammino-2-metil-4-ossochinazolin-3(4h)-il) piperidin-2,6-dione |
| EP2991651A1 (en) | 2013-05-03 | 2016-03-09 | Celgene Corporation | Methods for treating cancer using combination therapy |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| TW201540323A (zh) | 2014-01-15 | 2015-11-01 | Celgene Corp | ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物 |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| US20150258082A1 (en) | 2014-03-14 | 2015-09-17 | Francesco Parlati | Combination therapy with glutaminase inhibitors |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| EP3827836A1 (en) | 2014-06-27 | 2021-06-02 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| KR20170029565A (ko) | 2014-07-11 | 2017-03-15 | 셀진 코포레이션 | 암 치료를 위한 병용요법 |
| WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
| MX2017001620A (es) | 2014-08-07 | 2017-05-10 | Calithera Biosciences Inc | Formas cristalinas de inhibidores de glutaminasa. |
| US10092541B2 (en) | 2014-08-15 | 2018-10-09 | Celgene Corporation | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
| JP2017533727A (ja) | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| WO2016153948A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders |
| EP3277676B1 (en) | 2015-03-25 | 2023-03-22 | Pierre Fabre Médicament | Substituted quinazoline derivatives as dna methyltransferase inhibitors |
| TW201642857A (zh) | 2015-04-06 | 2016-12-16 | 西建公司 | 以組合療法治療肝細胞癌 |
-
2007
- 2007-09-25 ME MEP-2016-47A patent/ME02420B/me unknown
- 2007-09-25 PT PT111740569T patent/PT2420498T/pt unknown
- 2007-09-25 MX MX2009003038A patent/MX2009003038A/es active IP Right Grant
- 2007-09-25 EP EP11174059.3A patent/EP2428513B1/en active Active
- 2007-09-25 SI SI200731953T patent/SI2428513T1/sl unknown
- 2007-09-25 PT PT07838876T patent/PT2066656E/pt unknown
- 2007-09-25 WO PCT/US2007/020765 patent/WO2008039489A2/en not_active Ceased
- 2007-09-25 HU HUE11174055A patent/HUE026827T2/en unknown
- 2007-09-25 ME MEP-2012-60A patent/ME01421B/me unknown
- 2007-09-25 ZA ZA200901950A patent/ZA200901950B/xx unknown
- 2007-09-25 CN CN201510163088.3A patent/CN104910133A/zh active Pending
- 2007-09-25 LT LTEP11174056.9T patent/LT2420498T/lt unknown
- 2007-09-25 SI SI200730915T patent/SI2066656T1/sl unknown
- 2007-09-25 PL PL07838876T patent/PL2066656T3/pl unknown
- 2007-09-25 PL PL11174056T patent/PL2420498T3/pl unknown
- 2007-09-25 EP EP11174055.1A patent/EP2420497B1/en active Active
- 2007-09-25 RS RS20160160A patent/RS54607B1/sr unknown
- 2007-09-25 RU RU2009115653/04A patent/RU2463298C2/ru active
- 2007-09-25 NZ NZ575830A patent/NZ575830A/en unknown
- 2007-09-25 DK DK11174055.1T patent/DK2420497T3/en active
- 2007-09-25 AT AT07838876T patent/ATE555104T1/de active
- 2007-09-25 CN CN201510162174.2A patent/CN105017212A/zh active Pending
- 2007-09-25 HU HUE11174059A patent/HUE035389T2/en unknown
- 2007-09-25 CN CNA2007800426159A patent/CN101535291A/zh active Pending
- 2007-09-25 ME MEP-2017-152A patent/ME02890B/me unknown
- 2007-09-25 LT LTEP11174059.3T patent/LT2428513T/lt unknown
- 2007-09-25 DK DK11174059.3T patent/DK2428513T3/en active
- 2007-09-25 RS RS20120259A patent/RS52349B/sr unknown
- 2007-09-25 MY MYPI20091187 patent/MY150699A/en unknown
- 2007-09-25 HU HUE11174056A patent/HUE035308T2/en unknown
- 2007-09-25 KR KR1020097008299A patent/KR101414786B1/ko not_active Expired - Fee Related
- 2007-09-25 CL CL200702752A patent/CL2007002752A1/es unknown
- 2007-09-25 CN CN201510163104.9A patent/CN104876908A/zh active Pending
- 2007-09-25 EP EP07838876A patent/EP2066656B1/en active Active
- 2007-09-25 HR HRP20120447TT patent/HRP20120447T1/hr unknown
- 2007-09-25 SI SI200731756T patent/SI2420497T1/sl unknown
- 2007-09-25 ES ES11174059.3T patent/ES2634915T3/es active Active
- 2007-09-25 ES ES11174056.9T patent/ES2633818T3/es active Active
- 2007-09-25 RS RS20170707A patent/RS56279B1/sr unknown
- 2007-09-25 EP EP11174056.9A patent/EP2420498B1/en active Active
- 2007-09-25 CA CA2663731A patent/CA2663731C/en not_active Expired - Fee Related
- 2007-09-25 PL PL11174055T patent/PL2420497T3/pl unknown
- 2007-09-25 JP JP2009530406A patent/JP5388854B2/ja not_active Expired - Fee Related
- 2007-09-25 DK DK11174056.9T patent/DK2420498T3/en active
- 2007-09-25 UA UAA200904043A patent/UA94964C2/ru unknown
- 2007-09-25 SI SI200731950T patent/SI2420498T1/sl unknown
- 2007-09-25 CN CN201710560709.0A patent/CN107445940A/zh active Pending
- 2007-09-25 EP EP17165492.4A patent/EP3239144A1/en not_active Withdrawn
- 2007-09-25 PL PL11174059T patent/PL2428513T3/pl unknown
- 2007-09-25 ES ES07838876T patent/ES2385680T3/es active Active
- 2007-09-25 DK DK07838876.6T patent/DK2066656T3/da active
- 2007-09-25 ME MEP-2017-159A patent/ME02829B/me unknown
- 2007-09-25 CN CN2012103629552A patent/CN102898416A/zh active Pending
- 2007-09-25 ES ES11174055.1T patent/ES2564935T3/es active Active
- 2007-09-25 PT PT111740593T patent/PT2428513T/pt unknown
- 2007-09-26 AR ARP070104264A patent/AR063015A1/es active IP Right Grant
- 2007-09-26 PE PE2007001298A patent/PE20080970A1/es active IP Right Grant
- 2007-09-26 US US11/904,551 patent/US7635700B2/en active Active
- 2007-09-26 TW TW102116418A patent/TWI522351B/zh not_active IP Right Cessation
- 2007-09-26 TW TW096135832A patent/TWI399372B/zh not_active IP Right Cessation
-
2009
- 2009-03-19 IL IL197716A patent/IL197716A/en active IP Right Grant
- 2009-03-25 NI NI200900040A patent/NI200900040A/es unknown
- 2009-04-14 CR CR10712A patent/CR10712A/es unknown
- 2009-04-23 CO CO09041135A patent/CO6160323A2/es unknown
- 2009-12-11 US US12/636,651 patent/US8921385B2/en active Active
-
2012
- 2012-06-13 CY CY20121100536T patent/CY1112860T1/el unknown
- 2012-06-29 RU RU2012127334A patent/RU2617989C2/ru active
-
2013
- 2013-08-18 IL IL228017A patent/IL228017A/en active IP Right Grant
- 2013-10-08 JP JP2013210802A patent/JP5901599B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-24 US US14/552,337 patent/US9732064B2/en active Active
-
2015
- 2015-11-06 JP JP2015218025A patent/JP6133383B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-14 HR HRP20160266TT patent/HRP20160266T1/hr unknown
- 2016-07-12 AR ARP160102114A patent/AR105340A2/es unknown
-
2017
- 2017-02-28 IL IL250847A patent/IL250847A0/en unknown
- 2017-04-18 RU RU2017113360A patent/RU2017113360A/ru not_active Application Discontinuation
- 2017-04-19 JP JP2017082496A patent/JP2017165744A/ja not_active Ceased
- 2017-07-07 US US15/644,119 patent/US20170369471A1/en not_active Abandoned
- 2017-07-17 HR HRP20171093TT patent/HRP20171093T1/hr unknown
- 2017-07-18 HR HRP20171106TT patent/HRP20171106T1/hr unknown
- 2017-07-20 CY CY20171100778T patent/CY1119248T1/el unknown
- 2017-08-02 CY CY20171100831T patent/CY1119176T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010504973A5 (https=) | ||
| JP2010502627A5 (https=) | ||
| JP2009506117A5 (https=) | ||
| JP2013519675A5 (https=) | ||
| JP2018021046A5 (https=) | ||
| PH12019501098A1 (en) | Pyrrolopyrimidines as cftr potentiators | |
| JP2007514005A5 (https=) | ||
| GB0520751D0 (en) | Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease | |
| NZ599199A (en) | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same | |
| JP2017528507A5 (https=) | ||
| LTC1562603I2 (lt) | Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui | |
| WO2005097125A3 (en) | Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease | |
| JP2010513478A5 (https=) | ||
| JP2010529118A5 (https=) | ||
| SI2968312T1 (en) | Combination of Medicines | |
| JP2008539268A5 (https=) | ||
| JP2007536277A5 (https=) | ||
| BRPI0807749A2 (pt) | Composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos. | |
| WO2007048801A3 (en) | Sexual desire enhancing medicaments comprising benzimidazolone derivatives | |
| BRPI0606736A2 (pt) | combinação de compostos e esteróides de metilxantina para tratar doenças respiratórias crÈnicas | |
| BRPI0816255A2 (pt) | Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável | |
| CL2010000059A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-diflurobenzamida o una sal farmaceuticamente aceptable; forma polimorfica de la sal clorhidrato; composicion farmaceutica; y su uso para tratar una enfermedad del sistema nervioso central tal como dolor, sindrome metabolico, inflamacion, alzheimer. | |
| JP2008513510A5 (https=) | ||
| JP2018537507A5 (https=) | ||
| CO6410283A2 (es) | Métodos para administrar (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a través de la mucosa oral, la mucosa nasal o la piel, y sus compoisiciones farmacéuticas |